A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes [0.03%]
一项有关糖尿病人群吸入胰岛素肺毒性的真实世界数据分析
Todd L Burstain,Irl B Hirsch,Roy W Beck
Todd L Burstain
Background: Inhalation of technosphere insulin (TI) has been shown to significantly reduce postmeal glucose excursions compared with injections of rapid-acting analogue (RAA) insulin in people with diabetes. However, TI h...
The Development and Validation of Multivariable Electronic Health Record-Based Models to Predict Diabetic Ketoacidosis-Related Hospitalizations for Adults with Type 1 Diabetes [0.03%]
基于电子健康记录的多变量模型的发展和验证，用于预测1型糖尿病成人患者的糖尿病酮症酸中毒相关住院风险
Jacob Kohlenberg,Meng Xu,Ryan Coopergard et al.
Jacob Kohlenberg et al.
Aim: To develop and validate models that use electronic health record (EHR) data to predict diabetic ketoacidosis (DKA)-related hospitalizations over 90 and 180 days among adults with type 1 diabetes (T1D). ...
An Exploratory Analysis of Continuous Glucose Monitoring Metrics in Relation to Prediabetes in Youths with Obesity [0.03%]
肥胖青少年轻度血糖异常连续监测指标的探索性分析研究
Claudia Piona,Eleonora Maria Aiello,Valentina Mancioppi et al.
Claudia Piona et al.
Introduction: Youth obesity is a strong risk factor for prediabetes (PD) and type 2 diabetes. Current criteria for the diagnosis of PD/diabetes, including fasting glucose, 2-h blood glucose after oral glucose tolerance test (OGTT), and HbA1...
Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes [0.03%]
成人1型糖尿病患者使用Control-IQ技术与常规胰岛素治疗的费用效用分析
Jolien De Meulemeester,Francesca Fiorentino,Nuno Picado et al.
Jolien De Meulemeester et al.
Objective: This study evaluated the cost utility of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ) relative to multiple daily injections (MDIs) and standard insulin pump therapy, both used in combination with continuous ...
All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide [0.03%]
胰高血糖素样肽-1受体激动剂/葡萄糖依赖性促胰岛素多肽治疗1型糖尿病患者的全因死亡率和医疗资源利用率
Samita Garg,Sarah Kim,Andrew Ford et al.
Samita Garg et al.
Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with or without glucose-dependent insulinotropic polypeptide (GIP) are Food and Drug Administration approved for patients with type 2 diabetes (T2D) and weight loss and are i...
Twenty-Five Hours of Fasting with Automated Insulin Delivery in Youth with Type 1 Diabetes [0.03%]
一种针对1型糖尿病青年的自动化胰岛素输送25小时禁食法
Revital Nimri,Keren Smuel-Zilberberg,Michal Yackobovitch-Gavan et al.
Revital Nimri et al.
Introduction and Objective: Fasting presents unique metabolic challenges for individuals with T1D. The 25-h Yom Kippur complete fast provides an opportunity to evaluate whether automated insulin delivery (AID) systems can maintain metabolic...
Antigen-Specific Chimeric Antigen Receptor-T Regulatory Cells Home to Human Islets, Suppress Cytotoxic T Lymphocytes and Reverse Type 1 Diabetes [0.03%]
特异性抗原嵌合抗原受体修饰的调节性T细胞归巢至人胰岛抑制细胞毒性T淋巴细胞逆转1型糖尿病
Shahnawaz Imam,Pervaiz Dar,Shafiya Imtiaz Rafiqi et al.
Shahnawaz Imam et al.
Background: We have developed pancreatic beta-cell, antigen-specific, chimeric antigen receptor (CAR) T regulatory cells (Tregs) and explored their therapeutic potential for type 1 diabetes (T1D)/latent autoimmune diabetes of adults (LADA) ...
Letter: Response to: "Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia" [0.03%]
来信：针对“糖尿病前期及血糖正常者糖化血红蛋白与动态血糖监测指标无关”的回应
Simon Lebech Cichosz
Simon Lebech Cichosz
Time in Tight Range Versus Time in Range for Predicting Diabetic Retinopathy in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections: A Retrospective Longitudinal Study with isCGM Data [0.03%]
使用多次每日胰岛素注射的1型糖尿病成人中，预测糖网病的时间在紧范围内与时间范围内：具有isCGM数据的回顾性纵向研究
Fernando Sebastian-Valles,Elena García-Artacho,Alberto Santiago-Redondo et al.
Fernando Sebastian-Valles et al.
Background: Time in tight range (TITR, 70-140 mg/dL) has emerged as a glycemic metric offering stricter assessment than conventional time in range (TIR, 70-180 mg/dL). Whether TITR provides additional prognostic value for diabetic retinopat...
Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts [0.03%]
糖化血红蛋白和动态血糖监测估算血糖值的差异及其与血液常规指标的关系
Veronica Tozzo,David M Nathan,Heidi Krause-Steinrauf et al.
Veronica Tozzo et al.
Objective: Continuous glucose monitoring (CGM) and hemoglobin A1c (HbA1c) provide estimates of mean glycemia that may differ, in part, due to the effects of variation in red blood cell (RBC) age and turnover on HbA1c. Measurements derived f...